Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance

Hypertension

Volumn 46, Issue 2, 2005, Pages 313-320

  Ma, Ji ^a   Albornoz, Francisco ^a   Yu, Chang ^a   Byrne, Daniel W ^a   Vaughan, Douglas E ^a   Brown, Nancy J ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Angiotensin II; Plasminogen; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID RECEPTOR; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RENIN; SODIUM; SPIRONOLACTONE; TISSUE PLASMINOGEN ACTIVATOR; TRIAMTERENE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; MALE; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM URINE LEVEL; TREATMENT OUTCOME;

ADULT; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; ELECTROLYTES; FEMALE; FIBRINOLYSIS; HEMODYNAMIC PROCESSES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; RECEPTORS, MINERALOCORTICOID; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; TRIAMTERENE;

EID: 23244456665     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000174327.53863.86     Document Type: Article

References (38)

1. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
2. Pfeffer MA, Braunwald EA, Moyc LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Fiaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
3. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
5. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995;96:2515-2520.
6. Sawathipamich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab. 2002;87:448-452.
7. Oshima S, Ogawa H, Mizuno Y, Yamashita S, Noda K, Saito T, Sumida H, Suefuji H, Kaikita K, Soejima H, Yasue H. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J. 1997;134:961-966.
8. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1 in humans. Hypertension. 1998;32:965-971.
9. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab. 2000;85:336-344.
10. CaJo LA. Zaghctto F, Pagnin E, Davis PA, De Mozzi P, Sartorato P, Martirc G, Fiore C, Armanini D. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab. 2004;89:1973-1976.
11. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res. 1996;32:266-273.
12. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C, Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldostcrone-salt-induced fibrosis. Hypertension. 1999;33:981-986.
13. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dcehend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin H-induccd signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.
14. Brown NJ, Nakamura S, Ma L-J, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000;58:1219-1227.
15. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 2004;66:1493-1502.
16. Oestreicher EM. Martinez-Vasquez D, Stone JR, Jonasson L, Roubsanthisuk W, Mukasa K, Adler GK. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation. 2003;108:2517-2523.
17. Kenward MG, Jones B. The analysis of data from 2 × 2 cross-over trials with baseline measurements. Stat Med. 1987;6:911-926.
18. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241-2247.
19. Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type I receptor antagonism: differential effects on PAI-1 over time. Hypertension. 2002;40:859-865.
20. Lottermoser K, Hertfelder HJ, Vetter H, Dusing R. Fibrinolytic function in diuretic-induced volume depletion. Am J Hypertens. 2000;13:359-363.
21. Yalcin AU, Dincer M, Asian V, Gulhas Z. Effect of Spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25:260-264.
22. Eliasson M, Evrin PE, Lundblad D, Fibrinogen and Fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study. J Clin Epidemiol. 1994;47:513-524.
23. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 1997;78:656-660.
24. Province MA, Arnett DK, Hunt SC, Leiendecker-Foster C, Eckfeldt JH, Oberman A, Ellison RC, Heiss G, Mockrin SC, Williams RR. Association between the alpha-adducin gene and hypertension in the HyperGEN Study. Am J Hypertens. 2000;13:710-718.
25. Weinberger MH, Roniker B, Krause SL, Weiss RJ, Eplerenone a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-716.
26. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-2701.
27. Knauf H, Wais U, Lubcke R, Albiez, G. On the mechanism of action of triamterene: effects on transport of Na+, K+, and H+/HCO3- -ions. Eur J Clin Invest. 1976;6:43-50.
28. Martinez DV, Rocha R, Matsumura M, Oestreieher E, Ochoa-Maya M, Roubsanthisuk W, Williams GH, Adler GK. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension. 2002;39:614-618.
29. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
30. Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart. 2002;88:475-480.
31. Anonymous. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc. 1991;265:3255-3264.
32. Anonymous. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ. 1992;304:405-412.
33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc. 2002;288:2981-2997.
34. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
35. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
36. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309.
37. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
38. Zannad F, Alia F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.